Why is Pfizer stock falling after Q3 results?

seekingalpha02:26

Jeenah Moon/Getty Images NewsWall Street analysts reasoned out why Pfizer (NYSE:PFE) shares could be under pressure on Tuesday even as the New York-based pharma giant delivered better-than-expected ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479265726?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227739745/image_1227739745.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-10-30 02:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479265726","market":"other","top_or_hot":-1,"title":"Why is Pfizer stock falling after Q3 results?","media":"seekingalpha","content":"<div>\n<p>Jeenah Moon/Getty Images NewsWall Street analysts reasoned out why Pfizer (NYSE:PFE) shares could be under pressure on Tuesday even as the New York-based pharma giant delivered better-than-expected ...</p>\n\n<a href=\"https://seekingalpha.com/news/4220246-why-is-pfizer-stock-falling-after-q-3-results\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why is Pfizer stock falling after Q3 results?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy is Pfizer stock falling after Q3 results?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 02:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4220246-why-is-pfizer-stock-falling-after-q-3-results><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jeenah Moon/Getty Images NewsWall Street analysts reasoned out why Pfizer (NYSE:PFE) shares could be under pressure on Tuesday even as the New York-based pharma giant delivered better-than-expected ...</p>\n\n<a href=\"https://seekingalpha.com/news/4220246-why-is-pfizer-stock-falling-after-q-3-results\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.SGD","symbol_name":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","start_time":0,"source_url":"https://seekingalpha.com/news/4220246-why-is-pfizer-stock-falling-after-q-3-results","article_id":"2479265726","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227739745/image_1227739745.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479265726","pubTimestamp":1730226397,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Jeenah Moon/Getty Images NewsWall Street analysts reasoned out why Pfizer (NYSE:PFE) shares could be under pressure on Tuesday even as the New York-based pharma giant delivered better-than-expected fi","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4139":"生物科技","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4535":"淡马锡持仓","SG9999002232.USD":"Allianz Global High Payout USD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999002224.SGD":"Allianz Global High Payout SGD","BNTX":"BioNTech SE","LU0058720904.USD":"联博国际健康护理基金A","BK4568":"美国抗疫概念","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4588":"碎股","BK4550":"红杉资本持仓","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","PFE":"辉瑞","BK7095":"多种金属与采矿","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4551":"寇图资本持仓","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4581":"高盛持仓","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4548":"巴美列捷福持仓","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus"},"translate_title":"为什么辉瑞股价在第三季度业绩公布后下跌？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1,"BNTX":1},"content_text":"Jeenah Moon/Getty Images NewsWall Street analysts reasoned out why Pfizer (NYSE:PFE) shares could be under pressure on Tuesday even as the New York-based pharma giant delivered better-than-expected financials for Q3 2024 and raised its guidance. Pfizer’s (NYSE:PFE) topline for the quarter reached $2.8B, indicating ~32% YoY growth, beating Street forecasts by as much as $2.8B. However, the company attributed much of the outperformance to its COVID franchise, comprising its COVID pill Paxlovid and Comirnaty COVID vaccine developed with BioNTech (BNTX). Thanks mainly to U.S. sales amid a global COVID-19 wave, Paxlovid added $2.7B to the topline compared to $0.2M in the prior-year period when the company didn’t recognize sales from its home country ahead of a transition to commercial markets. Excluding Comirnaty and Paxlovid, Pfizer (PFE) said the topline expanded only 14% YoY operationally, raising concerns about the company’s non-COVID portfolio, which includes its blockbuster products Xeljanz and Ibrance.  Xeljanz, an anti-inflammatory therapy, generated $321M in sales with a ~36% YoY drop globally, and sales from cancer therapy Ibrance fell ~13% to $1.09B, both falling short of Street forecasts, according to Bloomberg data. Despite the guidance rise, Pfizer (PFE) reaffirmed its prior operational revenue growth target of 9%- 11% from last year, excluding the impact of Comirnaty and Paxlovid. JPMorgan analyst Chris Schott, who has a neutral rating on the stock, argued that Paxlovid largely drove the company’s Q3 beat. “Ultimately, we believe stronger new launch performance and/or further progress on the pipeline will be necessary to significantly change the narrative on the stock, which we see as more likely in 2H25 or beyond,” Schott added. Citi analyst Geoff Meacham, who has a similar rating on Pfizer (PFE), agreed. “We expect PFE shares to trade modestly up today as better 3Q results were largely driven by Paxlovid with no major changes to capital allocation strategies,” the analyst added. However, Cantor Fitzgerald’s Louise Chen said beat and raise supported her bullish thesis on PFE. “We continue to think there is a lot of value to be unlocked for PFE shares,” Chen added. Additionally, during the earnings call, Pfizer (PFE) CEO Albert Bourla was largely dismissive of activist investor Starboard Value’s calls to improve shareholder value. PFE shares spiked in early October amid reports that the New York-based hedge fund was pushing for changes at the company after building a ~$1B stake. “While we agree with some of the points they raised, we have vastly different views on many others,” Bourla said, specifically pointing to Starboard’s concerns on Pfizer’s (PFE) shareholder return and capital allocation strategy. “We believe that our deals will produce significant shareholder returns, and some of them, like Seagen or BioNTech, have been transformational for Pfizer,” Bourla said, adding, “We are executing on the best path forward to increase shareholder return.”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479265726"}